Literature DB >> 21733755

Pathology of post primary tuberculosis of the lung: an illustrated critical review.

Robert L Hunter1.   

Abstract

Post primary tuberculosis occurs in immunocompetent adults, is restricted to the lungs and accounts for 80% of all clinical cases and nearly 100% of transmission of infection. The supply of human tissues with post primary tuberculosis plummeted with the introduction of antibiotics decades before the flowering of research using molecular methods in animal models. Unfortunately, the paucity of human tissues prevented validation of the models. As a result, it is a paradigm of contemporary research that caseating granulomas are the characteristic lesion of all tuberculosis and that cavities form when they erode into bronchi. This differs from descriptions of the preantibiotic era when many investigators had access to thousands of cases. They reported that post primary tuberculosis begins as an exudative reaction: a tuberculous lipid pneumonia of foamy alveolar macrophages that undergoes caseation necrosis and fragmentation to produce cavities. Granulomas in post primary disease arise only in response to old caseous pneumonia and produce fibrosis, not cavities. We confirmed and extended these observations with study of 104 cases of untreated tuberculosis. In addition, studies of the lungs of infants and immunosuppressed adults revealed a second type of tuberculous pneumonia that seldom produces cavities. Since the concept that cavities arise from caseating granulomas was supported by studies of animals infected with Mycobacterium bovis, we investigated its pathology. We found that M. bovis does not produce post primary tuberculosis in any species. It only produces an aggressive primary tuberculosis that can develop small cavities by erosion of caseating granulomas. Consequently, a key unresolved question in the pathogenesis of tuberculosis is identification of the mechanisms by which Mycobacterium tuberculosis establish a localized safe haven in alveolar macrophages in an otherwise solidly immune host where it can develop conditions for formation of cavities and transmission to new hosts.
Copyright © 2011 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21733755      PMCID: PMC3215852          DOI: 10.1016/j.tube.2011.03.007

Source DB:  PubMed          Journal:  Tuberculosis (Edinb)        ISSN: 1472-9792            Impact factor:   3.131


  53 in total

1.  Exogenous reinfection as a cause of recurrent tuberculosis after curative treatment.

Authors:  A van Rie; R Warren; M Richardson; T C Victor; R P Gie; D A Enarson; N Beyers; P D van Helden
Journal:  N Engl J Med       Date:  1999-10-14       Impact factor: 91.245

Review 2.  Mycobacterium tuberculosis in the extracellular compartment: an underestimated adversary.

Authors:  Jacques Grosset
Journal:  Antimicrob Agents Chemother       Date:  2003-03       Impact factor: 5.191

Review 3.  Immune responses to tuberculosis in developing countries: implications for new vaccines.

Authors:  Graham A W Rook; Keertan Dheda; Alimuddin Zumla
Journal:  Nat Rev Immunol       Date:  2005-08       Impact factor: 53.106

Review 4.  Multiple roles of cord factor in the pathogenesis of primary, secondary, and cavitary tuberculosis, including a revised description of the pathology of secondary disease.

Authors:  Robert L Hunter; Margaret R Olsen; Chinnaswamy Jagannath; Jeffrey K Actor
Journal:  Ann Clin Lab Sci       Date:  2006       Impact factor: 1.256

5.  The role of the granuloma in expansion and dissemination of early tuberculous infection.

Authors:  J Muse Davis; Lalita Ramakrishnan
Journal:  Cell       Date:  2009-01-09       Impact factor: 41.582

6.  [Reevaluation of pathogenesis of epituberculosis in infants and children with tuberculosis].

Authors:  Shinya Kondo; Tomoo Miyagawa; Masaki Ito
Journal:  Kekkaku       Date:  2007-07

7.  In situ expression of CD40, CD40L (CD154), IL-12, TNF-alpha, IFN-gamma and TGF-beta1 in murine lungs during slowly progressive primary tuberculosis.

Authors:  S J Mogga; T Mustafa; L Sviland; R Nilsen
Journal:  Scand J Immunol       Date:  2003-09       Impact factor: 3.487

8.  On the response of genetically resistant and susceptible rabbits to the quantitative inhalation of human type tubercle bacilli and the nature of resistance to tuberculosis.

Authors:  M B LURIE; S ABRAMSON; A G HEPPLESTON
Journal:  J Exp Med       Date:  1952-02       Impact factor: 14.307

9.  High prevalence of tuberculosis in previously treated patients, Cape Town, South Africa.

Authors:  Saskia den Boon; Schalk W P van Lill; Martien W Borgdorff; Donald A Enarson; Suzanne Verver; Eric D Bateman; Elvis Irusen; Carl J Lombard; Neil W White; Christine de Villiers; Nulda Beyers
Journal:  Emerg Infect Dis       Date:  2007-08       Impact factor: 6.883

10.  The pathogenesis of epituberculosis in children with a note on obstructive emphysema.

Authors:  J H HUTCHISON
Journal:  Glasgow Med J       Date:  1949-08
View more
  73 in total

1.  Pulmonary TB: varying radiological presentations in individuals with HIV in Soweto, South Africa.

Authors:  Jesne Kistan; Fatima Laher; Kennedy Otwombe; Ravindre Panchia; Nohemie Mawaka; Limakatso Lebina; Andreas Diacon; Bavesh Kana; Neil Martinson
Journal:  Trans R Soc Trop Med Hyg       Date:  2017-03-01       Impact factor: 2.184

2.  CBA/J mice generate protective immunity to soluble Ag85 but fail to respond efficiently to Ag85 during natural Mycobacterium tuberculosis infection.

Authors:  Gillian L Beamer; Joshua Cyktor; David K Flaherty; Paul C Stromberg; Bridget Carruthers; Joanne Turner
Journal:  Eur J Immunol       Date:  2012-04       Impact factor: 5.532

Review 3.  The role of B cells and humoral immunity in Mycobacterium tuberculosis infection.

Authors:  John Chan; Simren Mehta; Sushma Bharrhan; Yong Chen; Jacqueline M Achkar; Arturo Casadevall; JoAnne Flynn
Journal:  Semin Immunol       Date:  2014-10-28       Impact factor: 11.130

4.  IL12B expression is sustained by a heterogenous population of myeloid lineages during tuberculosis.

Authors:  Allison E Reeme; Halli E Miller; Richard T Robinson
Journal:  Tuberculosis (Edinb)       Date:  2013-03-13       Impact factor: 3.131

Review 5.  Autophagy and inflammation in chronic respiratory disease.

Authors:  Alexandra C Racanelli; Sarah Ann Kikkers; Augustine M K Choi; Suzanne M Cloonan
Journal:  Autophagy       Date:  2018-02-08       Impact factor: 16.016

Review 6.  Tuberculosis as a three-act play: A new paradigm for the pathogenesis of pulmonary tuberculosis.

Authors:  Robert L Hunter
Journal:  Tuberculosis (Edinb)       Date:  2016-01-02       Impact factor: 3.131

7.  Computer-aided detection and quantification of cavitary tuberculosis from CT scans.

Authors:  Ziyue Xu; Ulas Bagci; Andre Kubler; Brian Luna; Sanjay Jain; William R Bishai; Daniel J Mollura
Journal:  Med Phys       Date:  2013-11       Impact factor: 4.071

8.  Attenuated heme oxygenase-1 responses predispose the elderly to pulmonary nontuberculous mycobacterial infections.

Authors:  Ranu Surolia; Suman Karki; Zheng Wang; Tejaswini Kulkarni; Fu Jun Li; Shikhar Vohra; Hitesh Batra; Jerry A Nick; Steven R Duncan; Victor J Thannickal; Adrie J C Steyn; Anupam Agarwal; Veena B Antony
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2016-09-30       Impact factor: 5.464

9.  Protection and Long-Lived Immunity Induced by the ID93/GLA-SE Vaccine Candidate against a Clinical Mycobacterium tuberculosis Isolate.

Authors:  Susan L Baldwin; Valerie A Reese; Po-Wei D Huang; Elyse A Beebe; Brendan K Podell; Steven G Reed; Rhea N Coler
Journal:  Clin Vaccine Immunol       Date:  2015-12-09

10.  Differential virulence and disease progression following Mycobacterium tuberculosis complex infection of the common marmoset (Callithrix jacchus).

Authors:  Laura E Via; Danielle M Weiner; Daniel Schimel; Philana Ling Lin; Emmanuel Dayao; Sarah L Tankersley; Ying Cai; M Teresa Coleman; Jaime Tomko; Praveen Paripati; Marlene Orandle; Robin J Kastenmayer; Michael Tartakovsky; Alexander Rosenthal; Damien Portevin; Seok Yong Eum; Saher Lahouar; Sebastien Gagneux; Douglas B Young; Joanne L Flynn; Clifton E Barry
Journal:  Infect Immun       Date:  2013-05-28       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.